Oncotarget

Research Papers:

Associations of plasma hepcidin with mortality risk in patients with coronary artery disease

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:109497-109508. https://doi.org/10.18632/oncotarget.22722

Metrics: PDF 1636 views  |  Full Text 3736 views

Xinrui Li1,*, Ding Ding1,*, Yuan Zhang2, Dongfang Su1, Min Wang1, Xuechen Chen1, Yan Yang1, Changjiang Hong2, Gang Hu3 and Wenhua Ling1

1Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China

2Department of Cardiology, General Hospital of Guangzhou Military Command of People’s Liberation Army, Guangzhou, Guangdong, China

3Chronic Disease Epidemiology Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, USA

*These authors have contributed equally to this work

Correspondence to:

Wenhua Ling, email: [email protected]

Keywords: hepcidin; coronary artery disease; mortality; cohort study

Received: January 02, 2017     Accepted: July 06, 2017     Published: November 27, 2017

ABSTRACT

Background: Increased blood hepcidin may be associated with the presence and promotion of atherosclerosis, the association of hepcidin with mortality among coronary artery disease (CAD) patients remains unknown. We sought to assess the relationship of hepcidin and all-cause and cardiovascular disease (CVD) mortality among CAD patients with and without acute coronary syndrome (ACS).

Methods and Results: This study included 759 patients with ACS and 526 patients with stable CAD. After an average follow-up of 4.1 years, 154 deaths were recorded, 114 were due to CVD. After adjusting for CVD risk factors and inflammatory markers, the plasma hepcidin was positively associated with all-cause and CVD mortality in the ACS patients, the multivariable-adjusted hazard ratios (HRs) across tertiles of hepcidin were 1.00, 2.18 (95% CI 1.23-3.94), and 2.82 (95% CI 1.59-5.12) for all-cause mortality (Ptrend=0.006), and 1.00, 2.20 (95% CI 1.12-4.05), and 2.64 (95% CI 1.41-5.65) for CVD mortality (Ptrend=0.01). The C-index and net reclassification improvement when including hepcidin in traditional CVD models were 1.6% and 21.5% for all-cause mortality, 1.4% and 23.5% for CVD mortality, respectively, (P<0.001).

Conclusions: Plasma hepcidin was positively associated with mortality in ACS patients. Hepcidin may be a potential biomarker for risk prediction in ACS patients.